Claire von Mollendorf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claire von Mollendorf has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
Dorj Narangerel
12 shared publicationsTuya Mungun
National Centre for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia
12 shared publicationsBujinlkham Suuri
National Center for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia
10 shared publicationsDashtseren Luvsantseren
National Center for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia
10 shared publications- Cattram Duong Nguyen
Murdoch Children's Research Institute
8 shared publications E. Kim Mulholland
Infection, Immunity and Global Health, Murdoch Children’s Research Institute, Parkville, Australia
8 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by SAGE Publications in Health Services Insights
- Vol. 19
Asia-Pacific Vaccine Research Network: Findings From a Pre-post Assessment of the First Trained Cohort
Background: Research network formation facilitates global health research collaboration, however, impact evaluations are limited. Our collaborative Asia-Pacific Vaccine Research Network (APVRN) aims to strengthen vaccine research capacity and partnerships and document impact. The network was established by our first Australia Awards Fellowship awardee cohort (2023). Objective: To describe knowledge and translation outcomes following the participation of fellows in a training program. Methods: Fellows attended three training workshops, co-designed and co-delivered using a case-based approach. A training evaluation included anonymised pre- and post-workshop surveys to assess topic knowledge. Results: Fifteen fellows from seven Asia-Pacific countries participated and indicated workshops were relevant to daily work. Prior to workshops, most fellows reported no or little knowledge of included topics. Following workshops, knowledge gain was reported across all topics. Conclusions: The APVRN demonstrated professional development with applied and shared learnings and mentoring of next generation of leaders. The network will promote public health in the Asia-Pacific through collective efforts and creation of opportunities for scientific collaboration.
- 4 November 2026
- Published by SAGE Publications in Health Services Insights
- Vol. 19
Open AccessAsia-Pacific Vaccine Research Network: Findings From a Pre-post Assessment of the First Trained Cohort
Background: Research network formation facilitates global health research collaboration, however, impact evaluations are limited. Our collaborative Asia-Pacific Vaccine Research Network (APVRN) aims to strengthen vaccine research capacity and partnerships and document impact. The network was established by our first Australia Awards Fellowship awardee cohort (2023). Objective: To describe knowledge and translation outcomes following the participation of fellows in a training program. Methods: Fellows attended three training workshops, co-designed and co-delivered using a case-based approach. A training evaluation included anonymised pre- and post-workshop surveys to assess topic knowledge. Results: Fifteen fellows from seven Asia-Pacific countries participated and indicated workshops were relevant to daily work. Prior to workshops, most fellows reported no or little knowledge of included topics. Following workshops, knowledge gain was reported across all topics. Conclusions: The APVRN demonstrated professional development with applied and shared learnings and mentoring of next generation of leaders. The network will promote public health in the Asia-Pacific through collective efforts and creation of opportunities for scientific collaboration.
- Open Access
- 21 September 2026
- Published by Springer Nature in Research Square
Immune responses and predictors of SARS-CoV-2 infection following a fourth dose of mRNA or protein-based COVID-19 vaccines
Evidence on immune responses following SARS-CoV-2 infection in individuals boosted with mRNA or protein vaccines are limited. We examined the immune responses following SARS-CoV-2 infection and evaluated immunological markers associated with infection among adults who received a fourth dose of either a bivalent mRNA COVID-19 vaccine (Moderna), an ancestral protein-based vaccine (Novavax), or no fourth dose. Of 496 participants, 153 (30.8%; Moderna n = 57, Novavax n = 52, control n = 44) self-reported at least one infection over 12 months. Serum samples collected at 28 days post-infection showed similar concentrations of binding IgG and surrogate virus neutralising antibodies against SARS-CoV-2 Ancestral and Omicron variants (BA.1, BA.4/5 and JN.1) across vaccine arms and control group. At 6 months post-fourth dose, higher antibody levels were associated with 3–42% lower odds of infection between 7–12 months. The time to infection from fourth-dose vaccination for 10% of participants was longer in the Moderna group compared with the Novavax (191 days [95%CI:138–225] vs 137 days [95%CI:63–199]). Immune response following SARS-CoV-2 infection was similar regardless of prior vaccine platform and a fourth dose mRNA vaccine may delay infection relative to protein-based vaccination. Antibody thresholds may be a useful marker for informing the timing of future booster doses.
- 21 September 2026
- Published by Springer Nature in Research Square
Open AccessImmune responses and predictors of SARS-CoV-2 infection following a fourth dose of mRNA or protein-based COVID-19 vaccines
Evidence on immune responses following SARS-CoV-2 infection in individuals boosted with mRNA or protein vaccines are limited. We examined the immune responses following SARS-CoV-2 infection and evaluated immunological markers associated with infection among adults who received a fourth dose of either a bivalent mRNA COVID-19 vaccine (Moderna), an ancestral protein-based vaccine (Novavax), or no fourth dose. Of 496 participants, 153 (30.8%; Moderna n = 57, Novavax n = 52, control n = 44) self-reported at least one infection over 12 months. Serum samples collected at 28 days post-infection showed similar concentrations of binding IgG and surrogate virus neutralising antibodies against SARS-CoV-2 Ancestral and Omicron variants (BA.1, BA.4/5 and JN.1) across vaccine arms and control group. At 6 months post-fourth dose, higher antibody levels were associated with 3–42% lower odds of infection between 7–12 months. The time to infection from fourth-dose vaccination for 10% of participants was longer in the Moderna group compared with the Novavax (191 days [95%CI:138–225] vs 137 days [95%CI:63–199]). Immune response following SARS-CoV-2 infection was similar regardless of prior vaccine platform and a fourth dose mRNA vaccine may delay infection relative to protein-based vaccination. Antibody thresholds may be a useful marker for informing the timing of future booster doses.
- Open Access
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
Trends and Inequalities in Pneumonia Indicators for Children in Lao People’s Democratic Republic: Analysis of the Multiple Indicator Cluster Surveys from 2000 – 2023
Background: Pneumonia remains a leading cause of child death in Lao People's Democratic Republic (PDR). This analysis summarises coverage and inequality trends of the Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea (GAPPD) pneumonia indicators and wasting rates for children 0), poor (CIX<0), or equality (CIX=0).Findings: GAPPD indicator coverage increased except for antibiotic treatment. Only EBF reached its target (50%). The GAPPD score increased from 18·7% to 67·2%, but was below target (84%). Absolute differences in GAPPD scores and wasting rates decreased across subgroups except ethnolinguistic groups. Higher coverage of GAPPD indicators except EBF was skewed toward the wealthy. Wasting distribution reached near-equality across wealth quintiles in 2023 (CIX=-0·01, 95%CI -0·07,0·04), but wasting rates nearly doubled between 2011 (5·9%) and 2023 (10·7%).Interpretation: Substantial progress occurred toward attaining pneumonia targets in Lao PDR. However, rising wasting rates may jeopardise further gains. Inequalities persist, especially for ethnic minorities. Targeted investments are essential to improve GAPPD coverage for vulnerable populations and address childhood wasting.
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTrends and Inequalities in Pneumonia Indicators for Children in Lao People’s Democratic Republic: Analysis of the Multiple Indicator Cluster Surveys from 2000 – 2023
Background: Pneumonia remains a leading cause of child death in Lao People's Democratic Republic (PDR). This analysis summarises coverage and inequality trends of the Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea (GAPPD) pneumonia indicators and wasting rates for children 0), poor (CIX<0), or equality (CIX=0).Findings: GAPPD indicator coverage increased except for antibiotic treatment. Only EBF reached its target (50%). The GAPPD score increased from 18·7% to 67·2%, but was below target (84%). Absolute differences in GAPPD scores and wasting rates decreased across subgroups except ethnolinguistic groups. Higher coverage of GAPPD indicators except EBF was skewed toward the wealthy. Wasting distribution reached near-equality across wealth quintiles in 2023 (CIX=-0·01, 95%CI -0·07,0·04), but wasting rates nearly doubled between 2011 (5·9%) and 2023 (10·7%).Interpretation: Substantial progress occurred toward attaining pneumonia targets in Lao PDR. However, rising wasting rates may jeopardise further gains. Inequalities persist, especially for ethnic minorities. Targeted investments are essential to improve GAPPD coverage for vulnerable populations and address childhood wasting.
- Open Access
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Risk Factors for Pneumococcal Carriage in Mongolian Adults with Community Acquired Pneumonia
Background: Pneumonia causes significant morbidity and mortality in adults globally. Pneumococcal carriage is a prerequisite for pneumococcal disease, but research in adults in low-middle-income countries is limited. We aimed to describe risk factors for pneumococcal carriage in hospitalised adults with pneumonia in Mongolia. Methods: Adults ≥18 years with clinical pneumonia were enrolled in a prospective hospital-based surveillance program in Ulaanbaatar from 2019-2022. Nasopharyngeal swabs were tested to detect pneumococci using lytA qPCR and molecular serotyping by DNA microarray and metagenomics. Logistic regression analysis compared those with and without pneumococcal carriage detection to identify associated risk factors. Findings: Of 3,442 adults, 3,178 met the clinical pneumonia case definition. The median age was 54 years and 27.3% of participants lived in informal (ger) housing, which typically used coal stoves for heating. Of 2,759 participants with nasopharyngeal swabs collected, 333 (12.1%) had pneumococcal carriage detected. Pneumococcal carriage was positively associated with heavy smoking (adjusted odds ratio [aOR] OR 1·79, 95% CI 1·08-3·00), informal housing (aOR 1·45, 95% CI 1·13-1·88) and male sex (aOR 1·47, 95% CI 1·12-1·93). Pneumococcal carriage was negatively associated recent antibiotic exposure (aOR 0·58, 95% CI 0·42-0·80) and admission during the COVID-19 period (aOR 0·24, 95% CI 0·18-0·32). Interpretation : We identified that cigarette and environmental smoke exposure was associated with pneumococcal carriage. Public health non-pharmaceutical interventions likely contributed to reduced carriage during the COVID-19 period. Policies to address indoor air pollution and smoking as well as adult pneumococcal vaccination may assist in reducing the pneumonia burden in high burden settings.
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRisk Factors for Pneumococcal Carriage in Mongolian Adults with Community Acquired Pneumonia
Background: Pneumonia causes significant morbidity and mortality in adults globally. Pneumococcal carriage is a prerequisite for pneumococcal disease, but research in adults in low-middle-income countries is limited. We aimed to describe risk factors for pneumococcal carriage in hospitalised adults with pneumonia in Mongolia. Methods: Adults ≥18 years with clinical pneumonia were enrolled in a prospective hospital-based surveillance program in Ulaanbaatar from 2019-2022. Nasopharyngeal swabs were tested to detect pneumococci using lytA qPCR and molecular serotyping by DNA microarray and metagenomics. Logistic regression analysis compared those with and without pneumococcal carriage detection to identify associated risk factors. Findings: Of 3,442 adults, 3,178 met the clinical pneumonia case definition. The median age was 54 years and 27.3% of participants lived in informal (ger) housing, which typically used coal stoves for heating. Of 2,759 participants with nasopharyngeal swabs collected, 333 (12.1%) had pneumococcal carriage detected. Pneumococcal carriage was positively associated with heavy smoking (adjusted odds ratio [aOR] OR 1·79, 95% CI 1·08-3·00), informal housing (aOR 1·45, 95% CI 1·13-1·88) and male sex (aOR 1·47, 95% CI 1·12-1·93). Pneumococcal carriage was negatively associated recent antibiotic exposure (aOR 0·58, 95% CI 0·42-0·80) and admission during the COVID-19 period (aOR 0·24, 95% CI 0·18-0·32). Interpretation : We identified that cigarette and environmental smoke exposure was associated with pneumococcal carriage. Public health non-pharmaceutical interventions likely contributed to reduced carriage during the COVID-19 period. Policies to address indoor air pollution and smoking as well as adult pneumococcal vaccination may assist in reducing the pneumonia burden in high burden settings.
- Open Access
- 15 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Epidemiological, immunological and virulence characteristics of persistent Streptococcus pneumoniae vaccine serotypes following vaccine introduction
Streptococcus pneumoniae vaccine serotypes can persist despite pneumococcal conjugate vaccine (PCV) introduction. To examine serotype persistence, we leverage 6,545 nasopharyngeal swabs collected from children hospitalised with pneumonia before and after PCV13 introduction in Mongolia. DNA microarray was used to identify changes in lineage composition within serotypes 6A, 6B, 14, 19F and 23F over the six-year surveillance period. Children carrying post-PCV lineages are less likely to have severe pneumonia (serotypes 6B, 14 and 19F) and be multi-drug resistant (serotypes 6A, 6B and 23F) than pre-PCV lineages. Of note, the post-PCV lineage of serotype 6B has lower antibody binding to capsule and expression of capsule genes, thinner capsule and is less virulent in mice compared with the pre-PCV lineage. Our data show that although vaccine serotypes can persist in vaccinated populations, vaccination may select less virulent lineages within vaccine serotypes. Therefore, considering factors beyond serotype is important when evaluating the true value of vaccination.
- 15 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessEpidemiological, immunological and virulence characteristics of persistent Streptococcus pneumoniae vaccine serotypes following vaccine introduction
Streptococcus pneumoniae vaccine serotypes can persist despite pneumococcal conjugate vaccine (PCV) introduction. To examine serotype persistence, we leverage 6,545 nasopharyngeal swabs collected from children hospitalised with pneumonia before and after PCV13 introduction in Mongolia. DNA microarray was used to identify changes in lineage composition within serotypes 6A, 6B, 14, 19F and 23F over the six-year surveillance period. Children carrying post-PCV lineages are less likely to have severe pneumonia (serotypes 6B, 14 and 19F) and be multi-drug resistant (serotypes 6A, 6B and 23F) than pre-PCV lineages. Of note, the post-PCV lineage of serotype 6B has lower antibody binding to capsule and expression of capsule genes, thinner capsule and is less virulent in mice compared with the pre-PCV lineage. Our data show that although vaccine serotypes can persist in vaccinated populations, vaccination may select less virulent lineages within vaccine serotypes. Therefore, considering factors beyond serotype is important when evaluating the true value of vaccination.
- Open Access
- 13 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (4) , 106727
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
- 13 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (4) , 106727
Open AccessImmunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia
- Open Access
- 1 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , e60-e68
Immunogenicity of Human Papillomavirus Virus Vaccine in a High-risk and Understudied Group: Female Sex Workers
Female sex workers (FSW) have multiple sexual partners and are at higher risk of human papillomavirus virus (HPV) infection. They could be a target group for HPV vaccination, but their expected immune response to the HPV vaccine is unclear due to potential exposure to the virus. We conducted a pilot study (NCT04590521) in Hai Phong, Vietnam to evaluate HPV vaccine immunogenicity among FSW aged 18–26 years. All participants received the standard 3-dose schedule (0, 2, and 6 months) of the quadrivalent Gardasil vaccine (4vHPV). Cervical swabs were collected at time of vaccination to detect high-risk HPV DNA and cervical abnormalities. Blood samples were collected at baseline and at 2, 3, 6, and 7 months after the first dose to determine neutralizing antibody (nAb) responses to HPV16 and HPV18, as well as related HPV52 and HPV58. A total of 63 FSW with a median age of 23.4 years (IQR, 21.6–25.4 years) were recruited. Prevalence of any high-risk HPV type and HPV16/18 infection at baseline was 28.6% (18/63) and 9.5% (6/63), respectively. Following the first dose, 90% and 55% of individuals were seropositive for HPV16 and HPV18, respectively. By month 7, all participants were seropositive to both HPV16 and HPV18. Higher nAb responses were observed among HPV-DNA–negative participants at baseline compared with HPV-DNA–positive participants after 2 and 3 doses (HPV16, geometric mean ratio [GMR] 2.97 and 1.63, P < .05; HPV18, GMR 2.83 and 1.49, P = .06). Three doses of 4vHPV elicited robust nAb to HPV16 and HPV18 among FSW. Further studies are needed to evaluate the effectiveness of HPV vaccination in FSW. Clinical Trials Registration.NCT04590521.
- 1 March 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , e60-e68
Open AccessImmunogenicity of Human Papillomavirus Virus Vaccine in a High-risk and Understudied Group: Female Sex Workers
Female sex workers (FSW) have multiple sexual partners and are at higher risk of human papillomavirus virus (HPV) infection. They could be a target group for HPV vaccination, but their expected immune response to the HPV vaccine is unclear due to potential exposure to the virus. We conducted a pilot study (NCT04590521) in Hai Phong, Vietnam to evaluate HPV vaccine immunogenicity among FSW aged 18–26 years. All participants received the standard 3-dose schedule (0, 2, and 6 months) of the quadrivalent Gardasil vaccine (4vHPV). Cervical swabs were collected at time of vaccination to detect high-risk HPV DNA and cervical abnormalities. Blood samples were collected at baseline and at 2, 3, 6, and 7 months after the first dose to determine neutralizing antibody (nAb) responses to HPV16 and HPV18, as well as related HPV52 and HPV58. A total of 63 FSW with a median age of 23.4 years (IQR, 21.6–25.4 years) were recruited. Prevalence of any high-risk HPV type and HPV16/18 infection at baseline was 28.6% (18/63) and 9.5% (6/63), respectively. Following the first dose, 90% and 55% of individuals were seropositive for HPV16 and HPV18, respectively. By month 7, all participants were seropositive to both HPV16 and HPV18. Higher nAb responses were observed among HPV-DNA–negative participants at baseline compared with HPV-DNA–positive participants after 2 and 3 doses (HPV16, geometric mean ratio [GMR] 2.97 and 1.63, P < .05; HPV18, GMR 2.83 and 1.49, P = .06). Three doses of 4vHPV elicited robust nAb to HPV16 and HPV18 among FSW. Further studies are needed to evaluate the effectiveness of HPV vaccination in FSW. Clinical Trials Registration.NCT04590521.
- Open Access
- 3 January 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia
Background: Limited research has focused on risk factors for community acquired pneumonia (CAP) in adults in low-middle income countries (LMICs). Mongolia has high rates of CAP hospitalisations with extreme winter temperatures and significant air pollution. We aimed to examine risk factors for severe CAP among hospitalised adults aged ≥ 18 years in Mongolia. Methods: Adults hospitalised with clinical CAP were enrolled over three years (2019–2022) into a prospective CAP surveillance program in four district hospitals in the capital city, Ulaanbaatar. Participants had clinical information and risk factors collected using a case report form. Nasopharyngeal swabs were collected and tested for Streptococcus pneumoniae (the pneumococcus), influenza and respiratory syncytial virus, while collected urine was tested for the pneumococcus. From 2020 only patients with a negative SARS-CoV-2 test were enrolled in the study. Severe CAP was defined as clinical CAP with intensive care unit admission or ≥ 2 severity signs (confusion, hypotension, tachypnoea or hypoxaemia). Multivariable logistic regression was used to derive adjusted risk factor estimates. Results: Overall, 3178 participants met the CAP study case definition and 10.1% had severe CAP. Pneumococcal carriage (aOR:2.67; 95% CI:1.88–3.79; p < 0.001), pneumococcal serotype-specific urine antigen detection positivity (aOR:1.69; 95% CI:1.11–2.57; p = 0.01), hospital admission within the last year (aOR:1.73; 95% CI:1.26–2.37; p = 0.001), underlying medical conditions (aOR:1.96; 95% CI:1.39–2.76; p < 0.001), cigarette smoking (aOR:1.53; 95% CI:1.08–2.16; p = 0.01) and alcohol intake (aOR:2.19; 95% CI:1.49–3.22; p < 0.001), were identified as risk factors for severe CAP on multivariable analysis. Conclusion: We identified key risk factors for severe CAP in hospitalised adults in urban Mongolia. If resources are limited, this data could be used to prioritise groups for vaccinations, alongside public health policies to decrease tobacco smoking and alcohol consumption.
- 3 January 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessFactors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia
Background: Limited research has focused on risk factors for community acquired pneumonia (CAP) in adults in low-middle income countries (LMICs). Mongolia has high rates of CAP hospitalisations with extreme winter temperatures and significant air pollution. We aimed to examine risk factors for severe CAP among hospitalised adults aged ≥ 18 years in Mongolia. Methods: Adults hospitalised with clinical CAP were enrolled over three years (2019–2022) into a prospective CAP surveillance program in four district hospitals in the capital city, Ulaanbaatar. Participants had clinical information and risk factors collected using a case report form. Nasopharyngeal swabs were collected and tested for Streptococcus pneumoniae (the pneumococcus), influenza and respiratory syncytial virus, while collected urine was tested for the pneumococcus. From 2020 only patients with a negative SARS-CoV-2 test were enrolled in the study. Severe CAP was defined as clinical CAP with intensive care unit admission or ≥ 2 severity signs (confusion, hypotension, tachypnoea or hypoxaemia). Multivariable logistic regression was used to derive adjusted risk factor estimates. Results: Overall, 3178 participants met the CAP study case definition and 10.1% had severe CAP. Pneumococcal carriage (aOR:2.67; 95% CI:1.88–3.79; p < 0.001), pneumococcal serotype-specific urine antigen detection positivity (aOR:1.69; 95% CI:1.11–2.57; p = 0.01), hospital admission within the last year (aOR:1.73; 95% CI:1.26–2.37; p = 0.001), underlying medical conditions (aOR:1.96; 95% CI:1.39–2.76; p < 0.001), cigarette smoking (aOR:1.53; 95% CI:1.08–2.16; p = 0.01) and alcohol intake (aOR:2.19; 95% CI:1.49–3.22; p < 0.001), were identified as risk factors for severe CAP on multivariable analysis. Conclusion: We identified key risk factors for severe CAP in hospitalised adults in urban Mongolia. If resources are limited, this data could be used to prioritise groups for vaccinations, alongside public health policies to decrease tobacco smoking and alcohol consumption.
- Open Access
- 13 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children in Papua New Guinea, Lao PDR, and Mongolia
Background: High nasopharyngeal pneumococcal carriage density is associated with severe pneumonia; however, little is known about factors that affect pneumococcal carriage density including pneumococcal vaccination. We describe pneumococcal density by clinical and demographic factors, and effect of 13-valent pneumococcal conjugate vaccine (PCV13) on density in Papua New Guinea (PNG), Lao People’s Democratic Republic (Lao PDR) and Mongolia, 3–6 years following national PCV13 introduction. Methods: Three prospective pneumococcal carriage surveillance studies enrolled children aged 2–59 months with acute respiratory infections in Lao PDR (2013–2019), and pneumonia in PNG (2016–2019) and Mongolia (2015–2019). Demographic and clinical factors were collected on interview and from medical records. Nasopharyngeal swabs were tested for pneumococci using lytA real-time quantitative PCR and molecular serotyping using DNA microarray. In unvaccinated children median pneumococcal carriage density was compared across relevant clinical and demographic factors using Wilcoxon rank sum or Kruskal Wallis tests. Quantile regression models were used to determine the association between pneumococcal density, vaccination status and number of PCV doses. Results: A total of 1009 (PNG), 532 (Lao PDR) and 621 (Mongolia) pneumococcal carriers were included. Of carriers with serotyping results, PCV13 serotype (VT) carriage was 36.1% (356/985) in PNG, 40.8% (189/463) in Lao PDR and 50.7% (270/532) in Mongolia. The median pneumococcal VT density was 6.25 log 10 GE/ml (genome equivalents per milliliter) (interquartile range [IQR] 5.66, 6.79) in PNG, 5.74 log 10 GE/ml (IQR 4.99, 6.40) in Lao PDR and 5.64 log 10 GE/ml (IQR 5.11, 6.32) in Mongolia. In PNG, Lao PDR and Mongolia, 54.4%, 51.1% and 34.9% pneumococcal carriers were fully vaccinated, respectively. There was no difference in VT pneumococcal density by relevant clinical and demographic factors in unvaccinated children. In PNG, VT density was slightly lower (-0.36, 95% confidence interval [CI] -0.61, -0.12; p = 0.004) among vaccinated compared with unvaccinated children, in particular those who received three doses (-0.37 95% CI -0.63, -0.10; p = 0.007). No differences were observed in Lao PDR and Mongolia. Conclusions: We demonstrated variable results across our three sites. Indirect PCV13 effects may have resulted in limited observed reductions in VT density in unvaccinated children. In PNG, PCV13 vaccination was associated with a decline in VT density. Trial registration: Not applicable.
- 13 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessEvaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children in Papua New Guinea, Lao PDR, and Mongolia
Background: High nasopharyngeal pneumococcal carriage density is associated with severe pneumonia; however, little is known about factors that affect pneumococcal carriage density including pneumococcal vaccination. We describe pneumococcal density by clinical and demographic factors, and effect of 13-valent pneumococcal conjugate vaccine (PCV13) on density in Papua New Guinea (PNG), Lao People’s Democratic Republic (Lao PDR) and Mongolia, 3–6 years following national PCV13 introduction. Methods: Three prospective pneumococcal carriage surveillance studies enrolled children aged 2–59 months with acute respiratory infections in Lao PDR (2013–2019), and pneumonia in PNG (2016–2019) and Mongolia (2015–2019). Demographic and clinical factors were collected on interview and from medical records. Nasopharyngeal swabs were tested for pneumococci using lytA real-time quantitative PCR and molecular serotyping using DNA microarray. In unvaccinated children median pneumococcal carriage density was compared across relevant clinical and demographic factors using Wilcoxon rank sum or Kruskal Wallis tests. Quantile regression models were used to determine the association between pneumococcal density, vaccination status and number of PCV doses. Results: A total of 1009 (PNG), 532 (Lao PDR) and 621 (Mongolia) pneumococcal carriers were included. Of carriers with serotyping results, PCV13 serotype (VT) carriage was 36.1% (356/985) in PNG, 40.8% (189/463) in Lao PDR and 50.7% (270/532) in Mongolia. The median pneumococcal VT density was 6.25 log 10 GE/ml (genome equivalents per milliliter) (interquartile range [IQR] 5.66, 6.79) in PNG, 5.74 log 10 GE/ml (IQR 4.99, 6.40) in Lao PDR and 5.64 log 10 GE/ml (IQR 5.11, 6.32) in Mongolia. In PNG, Lao PDR and Mongolia, 54.4%, 51.1% and 34.9% pneumococcal carriers were fully vaccinated, respectively. There was no difference in VT pneumococcal density by relevant clinical and demographic factors in unvaccinated children. In PNG, VT density was slightly lower (-0.36, 95% confidence interval [CI] -0.61, -0.12; p = 0.004) among vaccinated compared with unvaccinated children, in particular those who received three doses (-0.37 95% CI -0.63, -0.10; p = 0.007). No differences were observed in Lao PDR and Mongolia. Conclusions: We demonstrated variable results across our three sites. Indirect PCV13 effects may have resulted in limited observed reductions in VT density in unvaccinated children. In PNG, PCV13 vaccination was associated with a decline in VT density. Trial registration: Not applicable.